India's Ranbaxy Sees Generic Deal For Nexium Kicking Off This Year
This article was originally published in PharmAsia News
Executive Summary
A deal between Ranbaxy Laboratories and AstraZeneca for a generic version of the U.K.-based firm's proton pump inhibitor Nexium (esomeprazole) is set to take place by the end of this year, ending a delay of more than a year
You may also be interested in...
UK Supplements Marketer Makes No Effort To Back Up Ad Claims
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.
COVID-19: New Emergency Guidance From AAMI Targets Remote-Controlled Devices
Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.
Radical Shake-Up In Store For Entire EU Pharma Legislation
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
Need a specific report? 1000+ reports available
Buy Reports